Good day, everyone. My name is Niki, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's 4th Quarter 2025 Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star, then the number one on your telephone keypad. If you would like to withdraw your question, please press star, then the number two on your telephone keypad. I will now turn the call over to Mr. John Bedford, Vice President of Investor Relations. Mr. Bedford, you may begin your conference.

Good morning, everyone, and thanks for joining us on the call. With us today are Rainer Blair, our President and Chief Executive Officer, and Matt McGrew, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release, the slide presentation supplementing today's call, the reconciliations and other information required by SEC Regulation G, and a note containing details of historical and anticipated future financial performance are all available on the investors section of our website www.danaher.com under the heading quarterly earnings the audio portion of this call will be archived on the investors section of our website later today under the heading events and presentations and will remain archived until our next quarterly call a dial in One replay of this call will also be available until February 11, 2026. During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to results from continuing operations and relate to the fourth quarter of 2025, and all references to period-to-period increases or decreases in financial metrics are year-over-year. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals or are available only in certain markets. During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements except as required by law. With that, I'd like to turn the call over to Reiner.

All right, John, thank you, and good morning, everyone. We appreciate you joining us on the call today. We delivered a strong finish to the year with better-than-expected performance across the portfolio. We were particularly encouraged by continued strength in our bioprocessing business, along with improving momentum in diagnostics and life sciences. Our team's disciplined execution also enabled us to exceed our fourth quarter margin earnings and cash flow expectations. Now, during the quarter, end market trends across our businesses were broadly consistent with what we saw through the first three quarters of the year. In pharma, global monoclonal antibody production remained robust, and we were encouraged to see a modestly more favorable capital spending environment. We also continued to see a recovery in pharma R&D spending, while biotech demand remained Academic and government demand remained muted, but was stable sequentially, while clinical and applied end markets continued to perform well. Now, I'd like to take a moment to thank our associates for their efforts in 2025. They did a tremendous job leveraging the Danaher business system to navigate a dynamic geopolitical and policy environment while continuing to deliver for our customers and drive productivity gains across our businesses. Their dedication and passion for serving our customers enabled the launch of innovative of therapies and diagnostic solutions, drove share gains in many of our businesses, and reinforced Danaher's reputation as a trusted leader in life sciences and diagnostics. Now looking ahead, we expect the gradual end market improvements we saw through 2025 to continue, and we believe the combination of our differentiated portfolio, the power of the Danaher business system and the strength of our balance sheet positions Danaher for long-term value creation as we move into 2026 and beyond. So with that, let's take a closer look at our full year 2025 financial results. Sales were $24.6 billion and core revenue increased 2%. Our adjusted operating profit margin was 28.2% and adjusted diluted net earnings per common share of $7.80 were up 4.5%. We also generated $5.3 billion of free cash flow resulting in a free cash flow to net income conversion ratio of approximately 145%. Strong free cash flow generation is one of the most important metrics at Danaher, and 2025 marks the 34th consecutive year our free cash flow to net income conversion ratio exceeded 100%. Our earnings growth and strong free cash flow generation in the face of tariff-related cost pressures and significant productivity investments underscore the differentiated quality of our earnings and business models. Now, our continued investments in innovation drove an accelerated cadence of new product introductions across Danaher in 2025. These new technologies are helping customers develop and manufacture therapies and diagnostic tests faster and more efficiently, ultimately helping to improve healthcare outcomes. In biotechnology, Cytiva launched more than 20 new products across the biologics workflow. Upstream, new 500 and 2000 liter formats of the Accelrex X platform bioreactor are helping drive higher yields while reducing the time and cost of biologic drug manufacturing for our customers. Downstream, Cytiva strengthened its purification portfolio with the launch of two new protein 15A resins, MabSelect Sure 70, and MabSelect Prisma X, delivering cost-effective solutions for preclinical and clinical production without compromising quality. Now, these launches reinforce CITIVA's commitment to helping customers improve yields and lower manufacturing costs while maintaining high performance across the drug development lifecycle. In life sciences, CyX reinforced their leadership in mass spectrometry with the introduction of the Xenotos 8600. The 8600 delivers up to 30 times increased sensitivity versus previous platforms, accelerating proteomic research and enabling faster identification of disease pathways to help accelerate drug development timelines. Meanwhile, Beckman-Coulter Life Sciences expanded its flow cytometry portfolio with the mosaic spectral detection module, bringing spectral capabilities to the Cytoflex platform that enable flexible, high-precision, multi-parameter characterization for pharmaceutical researchers. In diagnostics, Beckman-Coulter Diagnostics expanded the DXi-9000 assay menu highlighted by progress in neurodegenerative disease, including the first-to-market automated, high-throughput BD tau research-use-only immunoassay, while continuing to expand cardiac and blood virus menus. These advances, combined with sensitivity up to 100 times greater than traditional immunoassay systems, enable faster, more accurate patient diagnoses and help pave the way for precision diagnostics. Finally, last week, Cepheid received FDA clearance for its expert GI panel, a multiplex PCR test that quickly detects 11 common gastrointestinal pathogens from a single patient sample. Leveraging Cepheid's advanced 10-color multiplexing technology on its gene expert installed base, this test simplifies GI testing workflows, helps guide appropriate treatment for high-risk patients and can aid in reducing the risk of outbreaks in healthcare and community settings. This panel marks another step forward in Cepheid's multiplex testing strategy, building on momentum from the 4-in-1 respiratory panel, the MVP panel, and women's health, with further multiplex introductions planned over time. So, these are just a few of the innovations from across Daner that are delivering meaningful customer impact while also driving clear financial results, including approximately 25% year-over-year growth and new product revenue. So with that, let's turn to our fourth quarter 2025 results in more detail. Sales were $6.8 billion in the fourth quarter, and we delivered 2.5% for revenue growth. Geographically, core revenues and developed markets increased low single digits, with North America essentially flat and Western Europe up mid-single digits. High growth markets were up mid-single digits, with solid growth outside of China, more than offsetting a low single-digit decline in China. Our fourth quarter adjusted gross profit margin of 58.2 percent and our adjusted operating trading profit margin of 28.3%, were both down 130 basis points as the impact of cost savings initiatives more than offset the positive impact of volume leverage. Adjusted diluted net earnings per common share of $2.23 were up 4% year-over-year, and we generated $1.8 billion of free cash flow in the quarter. So now let's take a closer look at our fourth quarter results across the portfolio and give Give you some color on our end markets today. Poor revenue in our biotechnology segment increased 6%. Poor revenue in discovery and medical declined at a high single digit rate in a quarter driven by a difficult prior year comparison in our medical filtration business and by declines in protein research instrumentation as academic research customers continued to face funding constraints. Poor revenue in bioprocessing grew high single digits with high single-digit growth in consumables and mid-single-digit growth in equipment. Consumables growth was supported by continued robust demand for commercialized therapies, particularly monoclonal antibodies. And we were also encouraged by the return to equipment revenue growth in the quarter and by a third consecutive quarter of sequential equipment order growth. The orders remain below historical levels. Current momentum in our equipment order book and funnels is concentrated around shorter cycle projects such as line additions and brownfield expansions with U.S. reshoring related greenfield investments expected to provide incremental upside over time. Now given the sustained and substantial activity levels at our customers over the last year, year, we anticipate high single-digit core revenue growth in bioprocessing for the full year, 2026. Growth is expected to be led by consumables, with our current backlog and order trajectory supporting equipment revenue improving to approximately flat for the year. So, we see a bright future ahead for Cytiva. Underlying biologic demand, which is the primary growth driver of our business, has grown at double-digit rates annually for more than a decade, and we expect strong demand growth to continue into 2026 and beyond. This outlook is supported by another year of robust FDA approvals for biologic medicines in 2025 and increased uptake of existing therapies during this year, which taken together drove global biologic revenues to surpass small molecule drugs for the first time. The development pipeline also remains strong with biologics expected to represent more than two-thirds of the top 100 drugs by 2030. So, these positive trends reinforce our confidence in the durability of long-term growth in the bioprocessing market and for Cytiva's leading franchise. Turning to our life sciences segment, core revenue increased 0.5%. Poor revenue in our life sciences instrument businesses was essentially flat in the quarter. Looking across end markets, we continued to see a modest recovery in pharma, particularly in Europe, while biotech demand remained stable. Academic and research demand was muted, especially in the U.S. and China, but was generally stable on a sequential basis, and clinical and applied markets remained healthy. Poor revenue in our life sciences consumables businesses declined in the quarter, primarily due to lower demand for plasmids and mRNA from two of our larger customers, as well as continued funding pressure across early stage biotech and academic research. We were encouraged to see another quarter of sequential improvement at APTAM as key commercial initiatives in pharma and recombinant proteins delivered solid growth, partially offsetting ongoing softness in academic research. Moving to our diagnostic set, poor revenue increased 2%. Poor revenue in our clinical diagnostics businesses grew mid-single digits with high single-digit growth outside of China. Notably, Leica Biosystems and Radiometer were each up nearly 10%, with broad-based strength across both instruments and consumables. Beckman Coulter Diagnostics also delivered another strong quarter, with mid-single-digit growth globally, led by high single-digit growth in immunoassay. This is Beckman's sixth consecutive quarter of mid-single-digit or better-core growth outside of China and caps off a year of sustained momentum across its innovation and commercial engines. In molecular diagnostics, respiratory revenue of approximately $500 million exceeded our expectation as customers purchased in anticipation of an active respiratory season, given the high prevalence of currently circulating respiratory viruses. Over the past several weeks, we've worked closely with the team to better understand seasonal trends and revisit our assumption for respiratory revenue in a typical year. And as a result, we expect respiratory revenue of approximately $1.8 billion for the full year 2026. This assumes a normal respiratory season and that testing protocols at our customers remain remain broadly consistent with what we've seen the last few years. Low double-digit growth across Cepheid's core non-respiratory test menu was highlighted by nearly 30% growth in sexual health and mid-teens growth in hospital-acquired infection assays. This strong performance reflects continued traction in Cepheid's growth strategy, including new menu additions, such as the MVP panel in women's health, enabling entry into new new care settings, and existing customers continuing to add both menu and instruments across their healthcare networks. So looking ahead, we're excited about the long runway for durable growth at Cepheod, supported by a robust pipeline for future menu additions and anticipated continued expansion of our leading global install base. Now let's briefly look ahead at expectations for the first quarter and the full year 2026. Looking across the portfolio, we're assuming bioprocessing growth will be similar to 2025, including continued strength in consumables driven by healthy growth in monoclonal antibody demand and our strong positioning across the biologics workflow. In life sciences, we're assuming a modest improvement in end markets, but assume growth will remain below historical levels given the current macro environment. And in diagnostics, we're assuming higher growth in 2026 due to moving past the peak of headwinds from policy changes in China and our expectation that we will continue to execute well globally. For the full year 2026, we anticipate core revenue growth in the 3% to 6% range. Additionally, we are initiating full year adjusted diluted EPS guidance in the range of $8.35 to $8.50. In the first quarter, we expect core revenue to be up low single digits, and additionally, we expect the first quarter adjusted operating profit margin of approximately 28.5%. So to wrap up, we're pleased with our solid finish to the year and proud of the work our teams did in 2025 to reliably support our customers through a dynamic macro environment. They did a tremendous job staying focused on what we can control, running the Danaher business system playbook to offset cost pressures and deliver productivity gains while continuing to invest in innovation for the long term. So looking ahead, we're encouraged by the momentum building across our portfolio and expect growth to accelerate as end markets continue to improve. Our strong positioning and attractive end markets and high-recurring revenue business models support our long-term expectation for high single-digit core growth with a differentiated margin and cash flow profile. So, with the powerful combination of our differentiated portfolio, talented team, and strong balance sheet, all powered by the Danaher business system, we feel well-positioned to create long-term shareholder value while making a meaningful, positive impact on human health. So, with that, I'll turn the call back over to John.

Thank you, Reiner. That concludes our formal comments. We're now ready for questions.

Thank you. And if you would like to ask a question, please press star 1 on your keypad. To leave the queue at any time, press star 2. Once again, that is star and 1 to ask a question. Our first question comes from Michael Riskin with Bank of America. Please go ahead. Your line is open.

Great. Thanks for taking the question, guys, and congrats on the front. Morning, Rana. Maybe just to kick things off, you're opening with a 3% to 6% core revenue guide that's consistent with kind of, you know, the framework you laid out on the 3Q call. But if you look at the various segment details you provided, it looks like the segment levels, if you kind of do the, you know, the sum of the parts, it gets you closer to that 3%, which, again, you've hinted at in the past. I'm just curious, you know, if you could talk about how much conservatism is embedded in that Or maybe, you know, what are the levers or what are the drivers you could see getting you closer to that six? You know, where you see potential for upside as you go through the year, if there's one segment or another that kind of sticks out to you.

Well, how about informing better, reinforce that over, and now we've converted that into our core growth guide, which is based on the expectation of continued recovery in our end markets. And to your point, let me give you a little color on those. was, first of all, we expect bioprocessing to remain strong at high single digits. We had an excellent finish to the year with customers and with our teams, and things are going really well for us there in terms of spec wins and orders and, of course, sales as well. And this should – this momentum should lead to continued strength in consumables. And for equipment, we were encouraged by that momentum that we saw in the fourth quarter, But we're assuming that equipment is flat for 2026, which is off of a mid-teens decline in 25. But that is supported by our current backlog. Sciences and our discovery and medical businesses, we expect those to be flat. And we're assuming some modest improvement in our end markets there. And that said, we do expect growth will improve through the year as our own comps ease, particularly in our life science consumables businesses. In the low single digits, we're assuming consistent mid-single-digit growth outside of respiratory in China. Now we think the volume-based procurement headwinds will moderate as we move through the year. We've taken a look at that number again here in terms of the endemic level, and we think that's probably fairly consistent with 2020. Setting up the year, based on these improving end markets and some of the momentum that we saw coming out of Q4, there's probably two clients end markets. We're seeing some of that. We want to see more of that, especially here in the U.S. We'd like to see that improved biotech funding environment fall through now to an increasing order book in that particular segment. So encourage, but continuing and accelerating life science research would be helpful in those life science ed markets as well. And then the other level is where, you know, seeing better than high single-digit growth for the year with equipment potentially accelerating or even consumables accelerating more as we see more biosimilars and map production increasing, those would be two areas that could produce additional upside to the guide.

That's helpful. And if I could follow up just on that point on the bioprocessing outlook for 2026, can you talk a little bit about, you know, the order book, maybe book-to-bill, how that's shaped up in the fourth quarter for consumables and for equipment? Just give us a little bit more clarity on the confidence that's driving that 26 outlook. You know, you've got – you still have easy comps and equipment, but a little bit tougher comps than consumables. So just for both the equipment and the consumable side, you know, what the orders look like exiting the year and how that supports next year's outlook.

Sure. The order book, single digit growth that we've been talking about for 2026, as you know, the lead times have gotten much shorter on the consumable side, so having a book to build there around one is exactly where it needs to be, so we feel very good about that. We've talked about equipment orders increasing sequentially here the last three quarters in a row and then of course we grew revenue in the fourth quarter so we feel comfortable that we're starting to head in the right direction their equipment as well but one one quarter of growth we're not ready to call that a trend yet but the orders coming out of the last three quarters are encouraging

thank you we will move next to Tycho Peterson with Jeffries please go ahead

your line is open. Hey, good morning. Ron, I would love to just hear a little bit more about, you know, the strength on CyX and, you know, how much of that is, you know, the new product versus maybe end market recovery, and where specifically are you seeing kind of end markets turn for the

better there? Single-digit growth here in the fourth quarter, and we're seeing a number of factors contribute to that. Certainly innovation with the Xenotop 8600 getting some nice tracks. actually continued improvement in the pharma end market there. It's the third quarter in a row that we saw in life sciences, the pharma end market being at growth. The clinical and applied markets were robust as well. As you know, Psychex is the gold standard there, and PFAS testing as just one example. And then lastly, I would say in the academic and government segment, that continued to be muted but not growing in the last quarter. So the end markets continuing to improve and that also contributed to sizes and the instruments group performance there in the fourth quarter.

And then maybe one from Matt on margins, you know, we got the first quarter operating margin data obviously, but how should we think about kind of, you know, the flow through of incrementals? You didn't really touch on the incremental cost out, you know, initiatives on the call, But how should we think about kind of a full-year, you know, margin target and progression throughout the year?

Yeah, I think the way I sort of think about it is kind of very similar to core growth, right? So I think we're kind of starting out the year at low single-digit core growth and, you know, very similar to what we saw here in Q4, and that is going to sort of accelerate through the year. So you'll see kind of a little easier comps here in life science consumables in the second half, some modest end-market improvements in life sciences that Rainer just alluded to. put in the easier comps in China DX and respiratory. I think what we'll see is sort of that low single-digit growth kind of build through the year. And earnings is going to follow that. I think you'll see that follow the trajectory of the core growth with certainly the second half and the fourth quarter probably being the biggest beneficiary of the 2025 cost actions. And so if you kind of go through that, I think you'll see the second half is certainly building up, but that's largely almost all the benefit from the cost actions in the fourth quarter.

Okay. And then just lastly, quickly, on bioproduction, I appreciate all the incremental caller. Any commentary specifically on China? You know, there were some mixed data points earlier this week from one of the companies that reported on China bioprocess, so curious if you're, you know, seeing anything abnormal there in terms of trend.

Processing business in China is coming off of a large comp, but the underlying activity level continues to strengthen there. You know that the biotech market there in particular has found some new momentum here as they are able to monetize some of those molecules that they're developing there, some new to the world, through licenses, through going public and other types of monetization. Processing should continue to have a positive development, And certainly, we expect China bioprocessing to grow in 2026.

Thank you.

Thank you. Our next question comes from Scott Davis with Nelius Research. Please go ahead. Your line is open.

Morning, Scott.

Good morning, guys. Seems a pretty encouraging commentary, particularly around bioprocess, but guys, I want to back up a little bit. like you did a fair amount of you know restructuring and such and that can be defined in a lot of different ways but is that can you help us understand a little bit of the postmortem other than just the you know the margin impact kind of what did you actually do as it relates to kind of you know either rooftops or you know headcount was is there tangible change in fixed assets

there anything that you can kind of talk about publicly here activity improved resulted in reducing as we noted in previous calls those are pretty

significant yeah okay it's a good a good non-answer Reiner I get it understood the flu season has been pretty nasty God knows it's cold up here a cold where you're at too but is there are you seeing a big pickup in orders here in January kind of I know that you had a strong you know probably pre-order season and 4q and such but have you seen a pretty sizable reload as you as the

cases have picked up well we start to be that's helpful thank you Reiner best of

See you guys.

Thank you. We will move next with Doug Schenkel with Wolf Research. Please go ahead. Your line is open.

Morning, Doug.

Morning, Reiner. Thanks for taking the questions. Starting on bioprocessing, you know, given the strength of equipment growth in the fourth quarter and favorable comparisons for really at least the first three quarters of 2026, It's a smidge surprising you didn't guide for maybe a little more growth at that line. Was there any pull forward of demand into Q4 and or is this just, you know, maybe some extra prudence as we sit here in January in what's been, you know, a tough environment and an unpredictable environment, you know, over the last few years?

Yeah, Doug, maybe I'll take that. What we saw sort of on the consumable side maybe six or eight quarters ago, you know, it's been – to see some growth, mid-single-digit growth out of the equipment. One quarter our trend does not make, about to where we've been. A few more data points to point to on the equipment side. I think it's, again, kind of demonstrated ability over the past year that we're just going to go ahead and guide the flat. I think it's a good place to start. Let's see how the year progresses, and we'll go from there.

Okay. That is helpful, Matt. And pivoting to capital deployment, you know, the business is clearly stabilizing. you got solid free cash flow as always, debt to EBITDA is below two. Can you just describe the M&A environment and your readiness and your priorities to potentially get a little more aggressive than you've been recently? I guess I'm trying to get at whether or not you feel that you're in a better spot now than maybe you were a couple quarters ago to move on something potentially more sizable and more aggressive if the opportunity were to present itself. Thank you.

I would say the M&A environment is more constructive, some valuations moving in the right direction. Interest rates have moderated a little bit towards M&A and our cultivation of those M&A targets. Looking at end markets that we believe have assets within that market that have defensible value or value creation opportunities that we can compound over time, And we do see that that continues to progress in the right direction. We see improving end markets. Our team is executing well, as manifested by the fall-through that you see on the business and the cash flow.

Thank you. We will move next with Jack Meehan with Nifron Research. Please go ahead. Your line is open.

Good morning, Jack.

Good morning. Hope you're doing well. I want to push on a couple of the guidance assumptions a little bit. The first is in life sciences. So 2025 is obviously an unusual year in terms of customer spending patterns. I was curious about your thoughts on 4Q as a jumping off point for 2026, you know, in so much that, you know, is it possible there were some pushouts from earlier in the year that might have come in, you know, around year end. And so, like, what can you build off of in 4Q versus what, you know, might be like an elevated base? Any thoughts on that?

So, Jack, I think we continue to see improvement in the pharma and market. That would be the third quarter in a row that we have seen that improvement, and we would expect that to continue here going forward. The clinical and the applied markets have been solid, have been muted. we could still have a bit of choppiness that we hear currently in the market. That's good. Okay. And then, Matt, I wanted to push a little bit more on the margin

puts and takes for 2026. So you talked about the $250 million cost actions. You also have the biotechnology segment, your highest margin segment growing the fastest. There's the VBP. Is there anything else that stands out? You know, I'm just trying to think about the 100 bps or more for the year.

Yeah, no, maybe let me give you just a little color on how we have 835 to 850 just to give you a simple frame of kind of what that is. I think that might be helpful. So we're assuming the low end of the core growth, like we've talked about, so think 3 to 4 percent, assuming 35 to 40 percent fall through. We're going to – we've got a 30-cent benefit from the 2025 cost actions. So that's in that 100 basis points of margin expansion. it is inclusive of this $0.30 benefit. And that, as you remember, was the savings, so it's $250 million. So that benefit is about $0.30. And then there's kind of some below the line stuff in FX, which, you know, obviously could go either way. So I just assume all that stuff kind of nets to zero. If you do that math, you get kind of $835 to $850. And so, you know, if we do better from a core growth perspective than 30 to 3 to 4%, you know, there's probably likely some upside here to EPS. But, you know, if we're just to kind of start the year with uh see how the year progresses and we'll go from there okay

thank you guys thank you our next question comes from patrick donnelly with city please go ahead

your line is open hey guys thanks for taking the question um maybe a follow-up on jack there on the life side business reiner it sounds like things are improving you know across the board abcam aldevaran cyx can you just run through what you saw into year end on that front you know was there a good budget flush. And then similarly, as we look at 26, it seems like that's still flattish for the year. It feels like there's some upside there. Can you just talk through what you need to see to get that number going to a few percent growth? And again, we'd love to dig into some of those verticals, Abcam, Aldebaran in particular.

Fourth quarter, like we said, the life science business was a little bit ahead of ours in particular, do a little bit better than anticipated. But we did see a little bit of a We're going to read across for that instrument business there, but nonetheless, we did see As we think about 26 markets, five markets will stay stable, and I think the upside that we're looking for in life sciences comes sort of out of two categories, one being in the academic and government area, we need to see more stabilization there around the spending discussions and the budgetary discussions, so that would be one point. And then we'd like to see biotech in particular take advantage of the improved funding environment that we've seen here over the last two, three quarters and start seeing that fall through into the order book. So that, I think, would be what we'd like to see to think about upside.

And then maybe just the Abcam piece, Reiner. You talked about seeing improvement throughout the quarter. It seemed like that was firming up a little bit. Just wanted to dig in there.

We're encouraged by what we're seeing here at AFSCAN, the business continued to improve here in the fourth quarter. In fact, we've seen now three months of growth, particularly driven by the recombinant protein in the pharma segment that we've been talking about. And, of course, the team has been working very hard on right-sizing the cost picture there to the business and to our earnings expectations going forward, and we see that. In fact, the operating margins are 500 basis points higher than when we acquired the business. And so we like what we see here for ASCAM and expect to continue to see that trend here in 2026 as well.

Understood. And then maybe a little bit of a longer term one. I think as you build this year, it seems like, again, Reiner, I think you touched on the gradual recovery a few times. You know, as we exit this year and move forward, it certainly feels like we're approaching more level of normalcy. what is the path back to the LRP that you guys have out there? Is that on the table as we look ahead? I know it's January 26th, but as we look ahead to future years, what is the path there, and what do you need to see to believe that that's on the table next year?

Well, I mean, I would say it's too early to comment on 2027 and beyond to the point you just made. But here's how we're thinking about it. I mean, fundamentally, our businesses are in excellent end markets, and those growth drivers that we've talked about are very much intact, and we expect those growth drivers to continue to, well, the proliferation of biologics, some of the advancements that we see in life science research, and then, of course, the diagnostics area, bringing those diagnostics much closer to the, we don't see any change to our long-term framework, And as these end markets continue to recover, we'll get back to that high single-digit growth over time.

Thank you. We'll move next with Dan Lernert with UBS. Please go ahead. Your line is open.

Thank you. Hi, Reiner. Thank you very much for taking the question. You've talked a couple of times about the importance of an improving biotech funding environment on your life sciences business. Can you remind us how sensitive would the biotech business segment be to an improvement in biotech funding?

We've additionally been in 10-15%.

I mean, it's not – there is some level of exposure, but it's not the majority of

Okay, thank you.

Just to reaffirm, most of our business in bioprocess, commercial, and then you have a mix of clinical and bio – 10-15% is probably in the biotech area. And we have been seeing some improved orders there in bioprocessing out of that space.

Understood. Thank you. And a quick follow-up, Reiner, you mentioned the reshoring topic as a longer-term theme in bioprocessing. Can you update us on how any of those conversations with customers have been trending over the past three months?

market a great deal with our teams and meeting with our customers, CDMOs, CEOs, you name it, to get a real sense of what's going on here as it relates to the demand picture and the reshoring question. That demand has been happening to see how this now plays out going forward. But we really believe we could be in the early innings of a long-term investment cycle. And as you know, we're really quite well positioned to support those investments going

Thank you very much.

Thank you.

Thank you. And we have time for one more question. That question comes from Dan Brennan with PB Cowen. Please go ahead. Your line is open.

Great, thanks. Hey, good morning, Reiner. I'm Matt. Thanks for the question. Maybe to start just back to bioprocess, if you don't mind, you know, with the biotech guide, it's 6% for the year. And I think you guys talked about discovery and medical flat. So that gets us to bioprocess growth, I think, around 6%, which is a bit lower than what I think you guys did in 25. So is that math correct? And, you know, I'm just wondering, would that imply like a bit of a slowdown that you're starting the year at for consumables? Given equipment is stronger, I know, Matt, you talked about conservatism. But if it's such a focus, I just want to kind of flush out how you're thinking about the starting point for the 26 guide.

For the year and for Q1, our assumption is that we'll grow high single digits out of We've seen in the end markets and no change to what we have been talking about for a while We are not seeing .

Okay. And then maybe just a final question just for life sciences. I know, Ryan, you gave a lot of color so far on the kind of moving pieces there, but, you know, academic, I don't know, maybe it's like 15% to 20% of life sciences, I'm guessing, so that remains muted. And I know in your guide, you kind of mentioned ongoing macro pressure. But I would think pharma is a big part of life sciences. And I would think with MFN and tariffs kind of behind us, hopefully you could see a really nice recovery on easy comes from pharma. So could you just unpack a little bit like on the pharma piece, kind of what you're seeing in life sciences and kind of how you kind of guide it and, you know, is there the chance for that to get better in 26? Thank you.

And when we say we expect end markets in life sciences specifically to the pharma end market. So think of research use only, testing, that sort of thing. We expect that to remain stable, the wide market to remain stable. Those are robust. There are potential upsides as the policy situation stabilizes and finds a –

Thank you. And we have reached our allotted time for questions. I will now turn the call back to John Bedford for closing remarks.

Thank you, Nikki, and everybody.

we're around for uh thank you this brings us to the end of danaher corporation's fourth quarter 2025 earnings results conference call we appreciate your time and participation you may now disconnect